Research Analysts Offer Predictions for BCYC Q1 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Equities research analysts at HC Wainwright decreased their Q1 2025 earnings per share estimates for Bicycle Therapeutics in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.99) per share for the quarter, down from their previous estimate of ($0.93). HC Wainwright has a “Buy” rating and a $33.00 price target on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Bicycle Therapeutics’ Q2 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.90) EPS, FY2026 earnings at ($4.31) EPS, FY2027 earnings at ($3.45) EPS, FY2028 earnings at ($1.56) EPS and FY2029 earnings at $1.20 EPS.

Bicycle Therapeutics (NASDAQ:BCYC) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative return on equity of 27.35% and a negative net margin of 450.64%. The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.47 million. During the same period in the prior year, the firm posted ($1.16) earnings per share. The business’s quarterly revenue was down 30.2% compared to the same quarter last year.

A number of other analysts have also recently issued reports on BCYC. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Stephens reaffirmed an “equal weight” rating and issued a $15.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. B. Riley cut their price objective on Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, JMP Securities cut their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.14.

Bicycle Therapeutics Stock Down 0.5 %

BCYC opened at $10.97 on Friday. Bicycle Therapeutics has a 12-month low of $10.81 and a 12-month high of $28.67. The stock has a market cap of $757.43 million, a price-to-earnings ratio of -3.33 and a beta of 0.93. The business has a 50 day moving average of $13.27 and a 200-day moving average of $19.40.

Institutional Trading of Bicycle Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in BCYC. Assetmark Inc. bought a new position in shares of Bicycle Therapeutics in the third quarter valued at approximately $34,000. Barclays PLC grew its holdings in shares of Bicycle Therapeutics by 878.3% in the fourth quarter. Barclays PLC now owns 2,612 shares of the company’s stock valued at $37,000 after acquiring an additional 2,345 shares in the last quarter. Avior Wealth Management LLC bought a new position in Bicycle Therapeutics during the fourth quarter valued at $57,000. China Universal Asset Management Co. Ltd. grew its holdings in Bicycle Therapeutics by 30.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company’s stock valued at $131,000 after purchasing an additional 2,191 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Bicycle Therapeutics by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company’s stock valued at $191,000 after purchasing an additional 1,782 shares during the period. 86.15% of the stock is owned by institutional investors.

Insider Activity

In other news, CAO Travis Alvin Thompson sold 2,686 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $15.00, for a total value of $40,290.00. Following the transaction, the chief accounting officer now directly owns 32,146 shares of the company’s stock, valued at $482,190. The trade was a 7.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Santiago Arroyo sold 4,943 shares of the business’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $14.09, for a total value of $69,646.87. Following the completion of the transaction, the insider now directly owns 69,057 shares in the company, valued at $973,013.13. This represents a 6.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,677 shares of company stock valued at $392,413 in the last ninety days. 8.50% of the stock is owned by company insiders.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.